📖 Your Q2 Earnings Guide: Discover the Stocks ProPicks AI Highlights to Jump Post-EarningsRead more

Point72 Asset Management established new holdings in Curis Inc

Published 04/01/2021, 05:23 PM
Updated 04/01/2021, 05:30 PM
© Reuters.  Point72 Asset Management established new holdings in Curis Inc
VRTX
-
BIIB
-
ACORQ
-
BCRX
-
BGC
-
CYTK
-
AEO
-
BFH
-
ANGI
-
MGNX
-
VRDN
-
OTIC
-
AFMD
-
PLAY
-
CHMA
-
CTMX
-
SYRS
-
KDMN
-
ANAB
-
TCDAQ
-
RVLV
-
BCYC
-
FULC
-

On the 22nd of March, Point72 Asset Management purchased 5.3 million Curis Inc (CRIS) shares for $68 million at an average price of $12.77 per share. Shares of Curis Inc are down -7.20% since the transaction.

Point72 Asset Management's holding in Curis Inc established a new holding of about 5.3 million shares with the purchase.

Point72 Asset Management first bought Curis Inc stock in the fourth quarter of 2020. Point72 Asset Management also owns Alnylam Pharmaceuticals Inc (ALNY), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Biogen Inc (NASDAQ:BIIB) and Dicerna Pharmaceuticals, Inc. (DRNA). Curis Inc is its number one position by number of shares and market value among pharmaceuticals stocks.

Other investors who also established new holdings in Curis Inc include Farallon Capital Management, the T. Rowe Price Equity Income Fund, and Victory Capital Management. Contrary to Point72 Asset Management, Millennium Management and Squarepoint Ops reduced CRIS shares.

Point72 Asset Management has also recently reduced their share in Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), Cytokinetics Inc (NASDAQ:CYTK), Otonomy, Inc. (NASDAQ:OTIC), Calithera Biosciences, Inc. (CALA), Chiasma Inc (NASDAQ:CHMA) and Fulcrum Therapeutics, Inc. (NASDAQ:FULC). The total value of the shares sold is estimated at around $29 million.

In addition, Point72 Asset Management established new holdings in Aeglea BioTherapeutics, Inc. (AGLE). Point72 Asset Management also increased their share in BioCryst (NASDAQ:BCRX) Pharmaceuticals Inc (BCRX) and Acorda Therapeutics Inc (NASDAQ:ACOR). The total value of the shares bought is estimated at around $45 million.

Point72 Asset Management also reduced their share in VYNE Therapeutics INC (VYNE), American Eagle Outfitters Inc (NYSE:AEO), Childrens Place Inc (PLCE), ANGI Homeservices Inc (NASDAQ:ANGI), Dave & Busters Entertainment Inc (NASDAQ:PLAY) and MacroGenics, Inc. (NASDAQ:MGNX). The total value of the shares sold is estimated at around $85 million.

In addition, Point72 Asset Management established new holdings in Miragen Therapeutics Inc (NASDAQ:VRDN), CytomX Therapeutics, Inc. (NASDAQ:CTMX), AnaptysBio, Inc. (NASDAQ:ANAB), Hims & Hers Health, Inc. (HIMS) and Paya Holdings Inc. (PAYA). Point72 Asset Management also increased their share in Alliance Data Systems Corp (NYSE:ADS), BGC Partners Inc (NASDAQ:BGCP), Affimed N.V. (NASDAQ:AFMD), Kadmon Holdings Inc (NASDAQ:KDMN), Bicycle Therapeutics plc (NASDAQ:BCYC), Revolve Group Inc (NYSE:RVLV), Tricida , Inc. (NASDAQ:TCDA) and Mereo BioPharma Group plc (MREO). The total value of the shares bought is estimated at around $304 million.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.